Table 4 of
Sen, Mol Vis 2011; 17:2552-2563. Table 4 of
Sen, Mol Vis 2011; 17:2552-2563.
Table 4. Demographic and laboratories characteristics of the Eales disease (ED) patients in proliferative stage (those underwent vitrectomy) and controls patients with macular hole underwent vitrectomy surgery
Characteristics |
ED patients (proliferative stage’ n=19) |
Control patients with macular hole (n=16) |
p value |
|---|---|---|---|
| Males: Females | 18:0 | 15:1 | 0.4571 |
| Mean age [years (SD)] | 31.8 (8.1) | 61.2 (7.5) | 0.0001* |
| Serum IL-6 (pg/ml) | 2.017 (0.5476) | 0.8886 (0.2589) | <0.0001* |
| Serum VEGF (pg/ml) | 324.96 (91.34) | 209.9 (98.475) | 0.0105* |
| Serum hsCRP(mg/l) | 1.02(0.685) | 0.9785(0.268) | 0.81 |
| Vitreous IL-6 (pg/ml) | 79.8 (48.53) | 12.53 (8.57) | <0.0001* |
| Vitreous VEGF (pg/ml) | 1058.3 (181.5) | 16.987 (14.836) | <0.0001* |
| Vitreous protein (mg/ml) | 3.482 (1.83) | 0.695 (0.389) | 0.0001* |
| Ratio of IL-6 to protein (pg/mg) | 27.39 (12.86) | 16.53 (8.65) | 0.0071* |
| Ratio of VEGF to protein (pg/mg) | 316.26 (106.32) | 26.48 (13.26) | 0.0001* |